Table 5.
Clinical study of tissue engineering strategies in the repair of articular cartilage injury
| Intervening measure | Research type | Studies/patients(n) | Treatment outcomes | Disease type | References |
|---|---|---|---|---|---|
| A cell-free collagen-hydroxyapatite osteochondral scaffold | Case series | 27 patients | This study highlights the safety and potential of the scaffold for the treatment of osteochondral knee defects with good clinical results and stable interim follow-up results | Cartilaginous lesions of the knee joint | Kon et al. [139] |
| The MaioRegen(®) scaffold is a cell-free biomimetic scaffold consisting of type I collagen and hydroxyapatite | Prospective therapeutic study | 10 patients | Treatment of osteochondral defects with biomimetic scaffolds resulted in incomplete cartilage repair and poor subchondral bone repair at 2.5 years of follow-up | Cartilaginous lesions of the knee and talus bones | Christensen et al., [145] |
| Cell-free osteochondral scaffold | Case series | 27 patients | Cell-free osteochondral scaffold implantation in the treatment of osteochondritis dissecans has shown good and stable results | Knee osteochondritis dissecans | Perdisa et al., [140] |
| A cell-free collagen type I scaffold | Case series | 28 patients | The application of this scaffold for large defects showed increased wear of the repair tissue and clinical failure in 18% of cases at 5-year follow-up | Cartilage defects of the knee | Schüttler et al., [146] |
| Scaffolds with hyaluronan and CS-based structure | retrospective comparative study | 81 patients | Both scaffolds are effective for cartilage healing, but neither has clinical or radiological advantage | Talus osteochondral lesions | Akmeşe et al., [147] |
| A cell-free aragonite-based scaffold | Case series | 13 patients | This scaffold is a safe and clinically effective implant for the treatment of small and medium-sized joint surface lesion in the distal femur. The implants showed satisfactory bone integration and osteochondral recovery for up to 3 years | Joint surface lesion of the knee | Van Genechten et al., [150] |
| The Igor scaffold | Case series | 21 patients | Patients using Igor scaffold reported reduced pain and increased activity, with most reporting good results | Locally restricted cartilage defects | Zak et al., [143] |
| Two scaffolds with hyaluronan-based and CS-based structure | Retrospective comparative study | 69 patients | Both scaffolds are useful for cartilage regeneration, but have no clinical or radiological advantage | Symptomatic condylar osteochondral lesions | Akmeşe et al., [148] |
| Collagen scaffold | Retrospective cohort study | 94 patients | The use of collagen scaffold may not affect clinical efficacy or imaging results | Osteochondral lesions of the talus | Gorgun et al., [149] |
| Scaffold-supported bone marrow-derived cells | Therapeutic case series | 64 patients | The scaffold was used to repair osteochondral lesions of the talus, and the clinical effect was significant and lasted for a long time | Osteochondral lesions of the talus | Buda et al., [141] |
| The 3D scaffold based on a bilayered collagen type I sponge | Case series | 23 patients | The use of this scaffold is a feasible method for the treatment of large focal osteochondral defects, and the recent clinical and imaging results are good | Cartilage damage and OA of the knee | Zak et al., [151] |
| MSCs-loaded fibrin glue scaffold | Retrospective cohort study | 54 patients | The International Cartilage Repair Society (ICRS) score was higher after the treatment of knee joint with fibrin glue loaded with MSCs | Osteoarthritic (OA) knees | Kim et al., [142] |
| Implant of hydrogel | Systematic review and meta-analysis | 50 studies/ 2846 patients | There were clinically and statistically significant improvements in pain scores (VAS and WOMAC) and functional scores (IKDC and Lysholm) after treatment of knee cartilage injury with hydrogels compared to before treatment | Knee joint cartilage regeneration | Hosseini et al., [144] |
MSCs: marrow mesenchymal stem cells; CS: chitosan